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Abstract
Background: Fibromyalgia (FM) is a musculoskeletal chronic pain syndrome that impacts negatively patient’s daily
lives. Its pathogenesis is characterized by a complex relationship between biological and psychosocial factors not
fully understood yet. Pain catastrophizing is associated with FM and is an important predictor of outcomes. This
study aimed to answer two questions: (i) whether the allele and genotype frequencies of BDNF Val66Met (rs6265)
polymorphism differs between FM patients and healthy controls (HC); and (ii) if the BDNF Val66Met polymorphism
is a factor that predicts pain catastrophizing in FM.
Methods: In a cross-sectional design, 108 FM patients and 108 HC were included. FM patients responded to the
Brazilian Portuguese version of the Pain Catastrophizing Scale (BP-PCS) to assess pain catastrophizing, as well as
other validated tools for anxiety (The State-Trait Anxiety Inventory - STAI), depression (Beck Depression Inventory II –
BDI-II) and functional aspects (Fibromyalgia Impact Questionnaire - FIQ; Central Sensitization Inventory validated
and adapted for Brazilian population - CSI-BP; Pittsburgh Sleep Quality Index - PSQI; and Resilience Scale). All
subjects were genotyped for the BDNF Val66Met polymorphism.
Results: Val allele was significantly more frequent in FM patients compared to the control group (p < 0.05). Also, FM
patients with Val/Val genotype showed more pain catastrophizing thoughts, and this genotype was significantly
associated with magnification and rumination dimensions of BP-PCS (p < 0.05). Furthermore, there were significant
differences in levels of anxiety and symptoms of depression, years of education, and the functional situation
between the FM and control groups.
Conclusions: The findings show an association of BDNF Val66Met polymorphism with pain catastrophizing in FM,
which opens new avenues to comprehend the interplay between molecular genetic characteristics and
neuroplasticity mechanisms underpinning FM.
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Background
The widespread chronic pain is a recognized cardinal
symptom of fibromyalgia [1, 2]. Nevertheless, manifesta-
tions of central sensitization syndrome (CSS), such as fa-
tigue, body stiffness, sleep disturbances, depression,
anxiety, cognitive problems, and pain catastrophizing co-
occur [1, 2]. The CSS refers to an amplification of pain
by central nervous system mechanisms, and it is consid-
ered a main mechanism generator of pain hypersensitiv-
ity in conditions such as FM [3].
Positive and negative emotions and attention state can
amplify the pain perception [4]. Pain catastrophizing is an
exaggerated negative mental set brought to bear during an
actual or an anticipated painful experience [5]. It com-
prises three dimensions: helplessness, magnification, and
rumination [5]. More severe pain, as well as higher levels
of pain behavior and disability, is detected in individuals
who score higher on measures of pain catastrophizing [6].
Pain catastrophizing is a psychological factor that mark-
edly predicts variability in the perception of pain as well as
in the development of chronic pain conditions [6]. It has
been associated with increased activity in pain-related
areas of the brain [7, 8], and a decrease in the functioning
of opioid-mediated endogenous analgesic systems [9].
Notably, the brain-derived neurotrophic factor (BDNF) is
involved in central sensitization phenomena [10].
The BDNF is a neurotrophin from the nerve growth
factor family implicated in several molecular processes
in the central nervous system (CNS) [11, 12] modulating
the formation, maturation, and plasticity of neuronal
synapses [13]. The BDNF strengthens excitatory (gluta-
matergic) synapses and weakens inhibitory (GABAergic)
synapses. Although preliminary, studies have indicated
that the BDNF polymorphisms can be proneness factors
to the severity of psychological symptoms associated
with chronic pain (e.g., anxiety, depression, etc.) [14, 15].
The most common single nucleotide polymorphism in
the BDNF gene (c.196G > A, dbSNP: rs6265) causes an
amino acid substitution of valine to methionine at amino
acid residue 66 (Val66Met; rs6265). This polymorphism
alters intracellular trafficking and packaging of pro-
BDNF and, consequently, the regulated secretion of the
mature peptide [16]. Individuals with one or two copies
of the BDNF Met allele seem to have decreased brain
plasticity [17]. According to recent genome-wide study,
the Val allele is related to a higher risk of chronic post-
surgical pain [18]. And, it has been associated with the
severity of depression [19, 20]). Thus, Val66Met poly-
morphism is a candidate for individual differences ob-
served in neuroplasticity and, therefore, in behavioral
pain conditions. Despite the well-known clinical rele-
vance of pain catastrophizing, the neurobiological under-
pinnings of the phenomenon have just begun to be
specified [21]. Furthermore, there is a persistent gap in
the literature to investigate whether inter-subject genetic
variation on BDNF Val66Met polymorphism might be a
predictive factor of pain catastrophizing.
Thus, this study aimed to answer two questions: (i)
whether the allele and genotype frequencies of BDNF
Val66Met polymorphism differs between FM patients
and HC; (ii) if the BDNF Val66Met polymorphism is a
factor that markedly predicts pain catastrophizing in
FM. Our hypothesis is that catastrophizing may be influ-
enced by genetic factors and pain catastrophizing can
predispose patients to more severe symptoms.
Methods
Design, settings and subjects
We conducted an exploratory cross-sectional study. This
study was reported following the Strengthening the
Reporting of Observational studies in Epidemiology
(STROBE) guidelines [22]. The Ethics Committee Board
of the Hospital de Clínicas de Porto Alegre (HCPA) and
Universidade Luterana do Brazil (ULBRA) approved the
protocol of this study. All participants consent overtly
before their participation.
Recruitment, inclusion and exclusion criteria
We recruited women older than 18. Patients were re-
cruited from outpatient palliative medicine and pain
clinics at a private-public hospital, physiotherapy clinics
from the metropolitan region of Porto Alegre, Brazil,
and by website and social network disclosure. Healthy
volunteers were recruited from a blood donation service
at the same hospital. Inclusion criteria for patients were:
previous diagnosis of FM according to the American Col-
lege of Rheumatology criteria [23]. Patients who presented
illicit drug abuse or comorbidity with oncological disease
were excluded. HC included in the study denied any con-
dition of chronic pain, fibromyalgia, systemic lupus ery-
thematosus, arthrosis, or rheumatoid arthritis or use of
antidepressant drugs. Both groups were recruited from
June 2016 to March 2018. FM patients were matched with
controls according to age and gender.
Dependent and independent variables of main interest
The dependent variable was the Brazilian Portuguese
version of the Pain Catastrophizing Scale (BP-PCS) (total
score) and its domains: helplessness, magnification, and
rumination (subscales’ scores) [24]. The main interest
factors were the genotypes of Val66Met BDNF (rs6265)
polymorphism.
Instruments and assessments
All tools, adapted and validated for the Brazilian popula-
tion, were responded by the clinical group, except the
Beck Depression Inventory II (BDI-II) and State-Trait
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Anxiety Inventory (STAI), which were answered by both
clinical and control groups.
a) Brazilian Portuguese version of the Pain
Catastrophizing Scale (BP-PCS [24];) was applied to
assess pain catastrophizing. It consists of 13 items
(rated on a 5-point Likert-type scale) to assess pa-
tient’s thoughts and feelings when they are in pain.
The scale is divided into three domains: helpless-
ness (6 items), magnification (3 items), and rumin-
ation (4 items). The BP-PCS total score ranges from
0 to 52 points. A cutoff score of 30 represents clin-
ically relevant level of catastrophizing [25].
b) Resilience Scale adapted for the Brazilian
population [26] was used to evaluate emotional
resilience, defined as levels of positive psychosocial
adaptation in the face of important life events. It
comprises 25 items rated on a 7-point Likert-type
scale and total score ranges from 25 to 175 points.
Higher scores indicate higher resilience.
c) Central Sensitization Inventory validated and
adapted for Brazilian population (CSI-BP [27]) was
applied to assess the severity of central
sensitization. The inventory consists of 25
statements rated on 5-point Likert-type scale re-
garding current health symptoms (part A). Informa-
tion about Central Sensitization Syndromes and
related conditions are collected in part B of the in-
ventory. The cutoff point suggested by CSI-BP is
35. The total score ranges from zero to 100.
d) The Brazilian validated version of the Fibromyalgia
Impact Questionnaire (FIQ [28];) was used to assess
the impact of FM in quality of life of patients. The
questionnaire consists of 10 items, and the higher
the score obtained, the greater the impact of
fibromyalgia on quality of life (maximum total score
is 100).
e) Pittsburgh Sleep Quality Index (PSQI) validated for
Brazilian Portuguese [29] was used to evaluate the
sleep quality and disturbances over a 1-month
period. The index consists of multiple-choice ques-
tions that investigate: frequency of sleep distur-
bances; subjective sleep quality; typical bedtime;
time of awakening; sleep latency; and, sleep dur-
ation. A global score ranges from zero to 21
whereas scores > 5 suggests poor sleep quality.
f) Brazilian Portuguese version of the Beck Depression
Inventory II (BDI-II [30];) was used to evaluate
depressive symptoms in patients and controls. The
BDI-II consists of 21 sets of statements about de-
pression symptoms regarding the last 15 days, is
rated from a zero to 3 ordinal scale (total score
ranges from zero to 63 points). Patients can be clas-
sified according to severity of symptoms: 0–13,
minimal/no depression; 14–19, mild depression;
20–28, moderate depression; and 29–63, severe
depression.
g) The State-Trait Anxiety Inventory (STAI) – short
version, adapted to Brazilian Portuguese with a
shorter version [31] was applied to evaluate anxiety.
The scale is Likert-type and divided in two parts for
the assessment of two types of anxiety: state-anxiety
- a fact-driven transient anxiety; and, trait-anxiety -
stable personality disposition, showing general level
of fearfulness. The score ranges from 13 to 52 for
the state-anxiety scale, and from 12 to 36 for the
trait-anxiety scale. Higher scores denote higher
levels of anxiety.
h) Standardized Questionnaire was used to assess
socio-demographic and health data (with extended
medical information questions for FM patients).
Genetic analyses
Blood samples were collected by venipuncture in 4ml
tubes containing Ethylenediamine tetraacetic acid
(EDTA), and centrifuged for plasma and cell separation.
Total DNA was purified using the method described by
Lahiri and Nurnberger [32]. The genotyping of Val66-
Met BDNF (rs6265) polymorphism was performed on a
StepOnePlus™ Real-Time PCR System (Applied Biosys-
tems Inc., Foster City, USA) using a predesigned Taq-
Man™ SNP genotyping assay (Thermo Fisher Scientific;
catalog 4,351,379, assay ID: C__11592758_10).
Statistical analyses
Descriptive data are presented as mean (M), standard
deviation (SD), standard error of mean (S.E.M.), fre-
quency and percentages (%). For the inferential analyses,
variables were compared between groups using Student’s
t test or the nonparametric Mann-Whitney test for con-
tinuous variables and the chi-square test for categorical
variables. Allele frequencies were determined by direct
counting of the alleles and departures from Hardy-
Weinberg equilibrium were evaluated by the chi-square
test. Correlations between variables were tested by Pear-
son’s r coefficient. All tests were two-tailed and per-
formed in SPSS software, version 18.0 (SPSS Inc., USA).
P < 0.05 was considered statistically significant.
Results
The study recruited 112 subjects with FM, nevertheless 3
subjects were excluded because did not meet the inclusion
criteria and one participant was excluded by problems
during blood collection. The sample comprises 216 sub-
jects (108 FM and 108 HC). Patients had the same geo-
graphic origin and are mainly of European ancestry. The
clinical and demographic characteristics of the FM sample
and controls groups are shown in Table 1. In the FM
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Table 1 – Socio-demographic and clinical characteristics of FM patients and controls (n = 216)
Characteristics FM(n = 108) Controls (n = 108) p
Age (years) 50.2 ± 9.5 49.5 ± 9.5 0.582
Body mass index (Kg/m2) 28.2 ± 4.6 27.0 ± 4.9 0.073
Years of education 10.3 ± 4.2 12.2 ± 4.1 0.001
White skin color 87 (80.6) 88 (81.5) 0.862
Functional situation 0.002
Employed 52 (48.1) 76 (70.4)
Unemployed 17 (15.7) 14 (13.0)
Retired 36 (33.3) 18 (16.7)
Other 3 (2.8) 0 (0.0)
FM diagnosis time (years) 6.4 ± 5.4 – –
Alcohol consumption 55 (50.9) – –
Number of times during the month (mean) 1.2 ± 2.2 – –
Smoke 22 (20.4) – –
Contraceptive pill 19 (17.6) – –
Psychiatric disordera 73 (67.6) – –
Mood disorders 57 (52.8) – –
Anxiety disorders 39 (36.1) – –
Other 4 (3.7) – –
Psychological or psychiatric treatment 35 (32.4) – –
Rheumatic or musculoskeletal condition (n = 80)a 64 (80.0) – –
Hypertension 36 (33.3) – –
Diabetes mellitus 9 (8.3) – –
Medications aiming pain reliefb 88 (81.5) – –
Central Nervous System active medication 77 (71.3) – –
Physical exercise 56 (51.9) – –
Number of days per week 1.6 ± 1.9 – –
Aerobic exercise 32 (29.6) – –
Anaerobic exercise 11 (10.2) – –
Aerobic and anaerobic exercise 13 (12.0) – –
Alternative practice for management pain 63 (58.3) – –
Psychological assessment, sleep quality, resilience, quality of life and CS symptoms
Beck Depression Inventory (BDI – II) 22.0 ± 12.7 3.5 ± 2.8 < 0.001
State-Trait Anxiety Inventory (STAI)
State - anxiety 28.1 ± 7.8 19.8 ± 5.4 < 0.001
Trace - anxiety 24.4 ± 5.2 16.4 ± 3.0 < 0.001
Total Brazilian Portuguese Catastrophizing Scale (BP-PCS) 32.5 ± 12.2 – –
BP-PCS - Helplessness 14.2 ± 6.0 – –
BP-PCS - Magnification 7.5 ± 3.4 – –
BP-PCS - Rumination 10.7 ± 3.6 – –
Resilience 128.3 ± 22.5 – –
Pittsburgh Sleep Quality Index (PSQI - BR) 10.8 ± 4.3 – –
Central Sensitization (CSI-BP) 58.0 ± 14.8 – –
Fibromyalgia Impact Questionnaire (FIQ) 61.2 ± 18.1 – –
Notes. Data are reported as number of subjects (% in parentheses) or mean and standard deviation (± S.D.). Student’s t test or Mann-Whitney test were
used for continuous data and Chi-square test was used for categorical data
a Multiple response
b Analgesics
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sample 81.5% of the patients used pain relief medications,
most (51.9%) performed physical exercise, mostly aerobic.
And, 58.3% of the patients searched for complementary
methods for pain management.
Among FM patients, 30.6% spontaneously reported
traumatic life events. Childhood traumatic experiences
reported through CSI-BP (item 24) were detected in
most patients (51.9%). When we compared socio-
demographic characteristics among FM and HC, there
were significant differences in years of education and
functional situation between groups. Indeed, as expected,
there were also significant differences in anxiety and de-
pressive symptoms, between FM and control groups
(Table 1).
Allele and genotype frequencies of the Val66Met
BDNF polymorphism are shown in Table 2. Allele fre-
quencies were significantly different between FM and
control groups (p < 0.05). The genotype frequencies are
in Hardy-Weinberg equilibrium in both groups.
The score on the BP-PCS was compared between Val/
Val and Val/Met genotypes in the FM patients (Fig. 1).
Val/Val genotype was significantly associated to magnifi-
cation and rumination domains (p < 0.05). FM patients
carrying the Val/Val genotype displayed higher scores in
pain catastrophizing scale (total score) and in the help-
lessness domain compared to the Val/Met genotype.
However, these differences were non-significant. Ana-
lysis of endophenotypes involved in FM and their associ-
ation with Val66Met BDNF polymorphism are shown in
Supplementary Table 1.
Total BP-PCS scores and subscores and total FIQ and
BP-SCI scores were correlated according to Val66Met
genotypes (Table 3). Impact of FM in quality of life of
patients showed positive relation with central
sensitization symptoms regardless of genotypes. Also,
catastrophizing showed positive relation with central
sensitization symptoms and impact of FM in quality of
life in both groups. However, strong and moderate posi-
tive correlations were mostly found in the Val/Met
group.
Discussion
In the present study the main findings are that Val allele
is more frequent in FM, while the Met allele is most fre-
quent in the control subjects, and that in FM the BDNF
Val/Val homozygotes are a potential genetic risk factor
associated with higher scores in the Pain Catastrophizing
Scale domains: magnification and rumination. From a
conceptual perspective, this emerging finding helps to
explain the neurobiology processes underpinning pain
catastrophizing. Its potential clinical relevance is aligned
with the view that pain catastrophizing has been a pre-
dictive factor of treatment response [5, 33]. Thus, it may
help to integrate the interplay between Val66Met poly-
morphism and clinical symptoms in the bedside clinical
assessment.
In this framework, the higher magnification and ru-
mination levels in the homozygotes Val/Val gives sup-
port for this hypothesis that this genotype do not
provide sufficient compensatory mechanisms to improve
the resilience of the neurobiological system involved in
the physiopathology of chronic pain, whereas the sever-
ity of these symptoms can be a dysfunctional response
related to somatosensory processes. This could an evi-
dence of a distinct subjective pain experience in those
with higher levels catastrophizing, somatization, depres-
sion, anxiety, and anger [34–36]. As have been noted,
these behaviors can indicate the patients have difficulties
in recruiting healthy coping strategies and exacerbate
psychological and clinical symptoms [37–39].
Accordingly, a previous study showed that individ-
uals Val/Val exposed to stressful events early in life
presented increased anxiety and higher volumes of
brain structures, such as the amygdala and medial
prefrontal gray matter [40]. Furthermore, in another
study evaluating anxiety, Val homozygotes had higher
levels of trait-anxiety compared to Met allele carriers
[14]. Also, an over-representation of the Val allele
and lower frequency of the Met allele was detected in
patients with bipolar disorders [41]. Likewise, an earl-
ier study with a similar perspective, showed that pain
catastrophizing was associated with the rs1176744
polymorphism of the serotonin receptor 3B (5-HT3B)
gene in healthy individuals [42].
Although the design of this study prevents estab-
lishing a cause-consequence relationship between the
Val66Met polymorphism and the rumination and
magnification in the FM, these findings may hold
Table 2 − Allele and genotype frequencies of the Val66Met
variant (n = 216)
FM Controls P
(n = 108) (n = 108)
Allele 0.045
Val (G) 195 (90.3) 181 (83.8)
Met (A) 21 (9.7) 35 (16.2)
Genotype model 0.069
Val/Val 87 (80.6) 77 (71.3)
Val/Met 21 (19.4) 27 (25.0)
Met/Met – 4 (3.7)
Met dominant modela 0.111
Val/Met + Met/Met 21 (19.4) 31 (28.7)
Val//Val 87 (80.6) 77 (71.3)
Notes. Data are presented as frequency and percentage (% in parentheses). P
values refer to comparison between FM allele and genotype frequencies and
controls and are based on Chi-square tests
a Met dominant model: OR = 1,67; 95% CI = 0.85–3.32
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clinical implications. One of them is the idea that
some genetic characteristics related to neuroplasticity
processes may predispose individuals with FM to
more severe clinical symptoms. Besides, they reinforce
the assumption that the severity of rumination and
magnification is a challenge in the management of
pain symptoms because they adversely compromise
the prognosis of FM. From the point of view of a coping
style, pain catastrophizing may become a maladaptive re-
sponse, leading to a substantial negative impact in the
quality of life of FM patients [43]. Furthermore, it is one
of the strongest predictors of the outcomes of therapeutic
approaches in chronic pain [5, 33].
The BDNF Val66Met polymorphism has been investi-
gated in several pathological conditions in humans [44–
46]. The Met allele was reported as a protective factor
against anxiety disorders due to its putative impairment
of amygdala-dependent aversive memory acquisition/
consolidation [47]. However, there is controversy regard-
ing which allele of Val66Met polymorphism is associated
with risk or protection (harmful or beneficial) in relation
to pathological conditions [41, 45–48]. It is possible that
the Met allele has pleiotropic effects. The downregula-
tion of synaptic plasticity by Met, particularly in excita-
tory glutamatergic circuits is discussed as protective
against psychiatric disorders [49], despite Met allele be-
ing associated with reduced cognitive performance,
which suggests decreased brain plasticity [16, 17, 50, 51].
According to an earlier study in a paradigm of use-
dependent plasticity, authors found reduced changes in
motor cortical excitability in Met carriers [52]. Although
we are aware that our results open a way to advance in
the comprehension of the complex pathophysiology of
FM, which is mediated by multiple systems (i.e.,
GABAergic, glutamatergic, noradrenergic, serotonergic,
etc.), this findings need to be interpreted cautiously.
Fig. 1 Pain catastrophizing scale (total and sub-scales’ scores) in the FM sample according to Val66Met genotypes. Notes. Data are shown as
mean and error standard of mean (S.E.M.)
Table 3 - Correlation between pain catastrophizing, central sensitization and impact of fibromyalgia according to genotype (n = 108)
Val/ Val (n = 87) Val/Met (n = 21)
BP-SCI FIQ BP-SCI FIQ
Fibromyalgia Impact Questionnaire (FIQ) r = .64a r = .74a
Pain Catastrophizing Scale (BP-PCS) total score r = .39a r = .36a r = .68a r = .55a
BP-PCS - Helplessness r = .47a r = .40a r = .72a r = .58a
BP-PCS - Magnification r = .25b r = .27b r = .54b r = .41a
BP-PCS - Rumination r = .30a r2 = .28a r = .63a r = .55b
a. Correlation is significant at the 0.01 level (2-tailed)
b. Correlation is significant at the 0.05 level (2-tailed)
Brazilian Portuguese Central Sensitization Inventory (BP-SCI); Brazilian Portuguese Pain Catastrophizing Scale (BP-PCS)
Silveira Alves et al. Advances in Rheumatology           (2020) 60:39 Page 6 of 9
Aligned with this perspective of the relationship be-
tween the BDNF polymorphism and clinical symptoms,
it is plausible that Met allele determine some mecha-
nisms associated with the improvement of dysfunctional
circuits involved in the imbalance of excitatory and in-
hibitory systems underlying pain catastrophizing. This
hypothesis finds some support in a previous study that
found a positive correlation between pain catastrophiz-
ing and cortical disinhibition [2]. Another study gives
support for this assumption as well, due to the authors
found an association between increased cortical disinhib-
ition and higher serum levels of BDNF in chronic pain
[53]. From a theoretical perspective, this association may
indicate a deteriorated function of cortical inhibition.
BDNF Val66Met frequencies vary widely among differ-
ent populations [48]. We detected significant differences
in allele frequencies of the BDNF Val66Met polymorph-
ism between FM patients and controls. The frequency of
the minor allele (Met) (16.2%) observed in our control
group was consistent with those previously reported in
control groups of studies performed in the Brazilian
population [54, 55].
Certain limitations must be considered in the inter-
pretation of our findings. First, despite our sample size
was large in comparison to previous reports in the litera-
ture concerning genetic variants of FM [56–61], its stat-
istical power is limited. Second, this is a cross-sectional
study, which may limit causality identification of the
demographic and clinical variables investigated. Finally,
it is not simple to understand how to apply this know-
ledge about pain catastrophizing and BDNF Val66Met
polymorphism in the clinical practice.
Conclusion
In conclusion, the present study showed an association
between Val66Met BDNF polymorphism with the FM,
providing new insights into the genetically specified pro-
cessing of pain catastrophizing. However, further studies
are needed to elucidate if the role of Val66Met BDNF
polymorphism could help to plan personalized thera-
peutic approaches in FM.
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